| Name | Title | Contact Details |
|---|
Tibotec (tee-bo-tek) Therapeutics was established in March 2003 as a division of Ortho Biotech Products, L.P. Headquartered in Bridgewater, N.J., the organization is dedicated to providing innovative virology therapeutics that help healthcare
Oxford Finance Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Nitrome Biosciences has discovered and identified a new class of enzymes.
SoundBite Medical is a medical devices company that began operations in May 2015, with its R&D facilities in Sherbrooke and commercialization headquarters in Montreal, Quebec. The Company is developing and commercializing proprietary wire-based device and generator console that delivers safe shockwave energy within the cardiovascular system to treat chronic total occlusions.
Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor platform. Established in 2008, the Company aims to utilize the body`s own machinery – the T-cell – to target and destroy cancer cells by using engineered, increased affinity T-cell receptors (TCRs) as a means of strengthening natural patient T-cell responses. Adaptimmune`s lead program is an affinity enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types. In June 2014, Adaptimmune announced that it had entered into a strategic collaboration and licensing agreement with GlaxoSmithKline (GSK) for the development and commercialization of the NY-ESO TCR program in partnership with GSK. In addition, Adaptimmune has a number of proprietary programs and its next TCR therapeutic candidate, directed at MAGE A-10, is scheduled to enter the clinic in 2015. The Company has identified over 30 intracellular target peptides preferentially expressed in cancer cells and is currently progressing eight of these through unpartnered research programs. Adaptimmune has over 150 employees and is located in Oxfordshire, UK and Philadelphia, USA.